Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5′-triphosphate exposure to support posology for SARS-CoV-2

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

(2020) Manli Wang et al.   CELL RESEARCH

Arguments in favor of remdesivir for treating SARS-CoV-2 infections

(2020) Wen-Chien Ko et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

A rational roadmap for SARS‐CoV‐2/COVID‐19 pharmacotherapeutic research and development. IUPHAR Review 29

(2020) S.P.H. Alexander et al.   BRITISH JOURNAL OF PHARMACOLOGY

Prioritisation of Anti‐SARS‐Cov‐2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics

(2020) Usman Arshad et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency

(2020) Calvin J. Gordon et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro

(2020) Ka-Tim Choy et al.   ANTIVIRAL RESEARCH

A prospective, randomized, open-label trial of early versus late favipiravir in hospitalized patients with COVID-19

(2020) Yohei Doi et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antiviral activity and safety of remdesivir against SARS-CoV-2 infection in human pluripotent stem cell-derived cardiomyocytes

(2020) Seong Woo Choi et al.   ANTIVIRAL RESEARCH

Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection

(2020) Nicolas Venisse et al.   ANTIVIRAL RESEARCH

Favipiravir at high doses has potent antiviral activity in SARS-CoV-2−infected hamsters, whereas hydroxychloroquine lacks activity

(2020) Suzanne J. F. Kaptein et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

GRL-0920, an Indole Chloropyridinyl Ester, Completely Blocks SARS-CoV-2 Infection

(2020) Shin-ichiro Hattori et al.   mBio

Phase 2a, open-label, dose-escalating, multi-center pharmacokinetic study of favipiravir (T-705) in combination with oseltamivir in patients with severe influenza

(2020) Yeming Wang et al.   EBioMedicine

Influenza virus polymerase inhibitors in clinical development

(2019) Frederick G. Hayden et al.   CURRENT OPINION IN INFECTIOUS DISEASES

Intracellular conversion and in vivo dose response of favipiravir (T-705) in rodents infected with Ebola virus

(2018) Sandra L. Bixler et al.   ANTIVIRAL RESEARCH

Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted

(2017) Thi Huyen Tram Nguyen et al.   PLoS Neglected Tropical Diseases

Predicting apparent passive permeability of Caco-2 and MDCK cell-monolayers: A mechanistic model

(2017) Kai Bittermann et al.   PLoS One

Clinical Pharmacokinetics and Pharmacodynamics of Ledipasvir/Sofosbuvir, a Fixed-Dose Combination Tablet for the Treatment of Hepatitis C

(2016) Polina German et al.   CLINICAL PHARMACOKINETICS

In VitroVirology Profile of Tenofovir Alafenamide, a Novel Oral Prodrug of Tenofovir with Improved Antiviral Activity Compared to That of Tenofovir Disoproxil Fumarate

(2015) Christian Callebaut et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Favipiravir (T-705), a novel viral RNA polymerase inhibitor

(2013) Yousuke Furuta et al.   ANTIVIRAL RESEARCH

Plasma and Intracellular Population Pharmacokinetic Analysis of Tenofovir in HIV-1-Infected Patients

(2011) Gautam Baheti et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cells

(2009) D. F. Smee et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY